BOCA RATON, FL., Nov. 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on...
Carlsbad, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc., (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for...
Conference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq:...
BURLINGAME, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- James T. Rosenbaum, MD, Senior Vice President of Research at Corvus Pharmaceuticals...
Continued Progress in Pepinemab Oncology and Neurology Clinical ProgramsPromising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab...
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate...
Ongoing INOpulse® REBUILD Phase 3 trial enrollment completion expected in the first quarter of 2023, with pivotal top-line data readout...
BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
– Cash Position of $21.3 Million as of September 30, 2022 – – Hosting Phase 3 REGAL Study Update Webcast...
- SHINE Alzheimer’s Trial Expands to European Sites - - SEQUEL Alzheimer’s Trial Awarded Additional NIA Grant to Complete -...
Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ:...
Continued execution to advance exebacase and CF-370 into new clinical studiesYONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation...
NEW ORLEANS and LONDON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies...
Financing led by Wellington Management with participation from other leading healthcare fundsCARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- MBX...
NORCROSS, Ga., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
-- Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron’s Phase 2a trial...
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update Global trial of sonelokimab in Hidradenitis Suppurativa...
Conference Call Today at 11:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
Paltusotine’s Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data in Q3 2023 Paltusotine lowered...
Healthy volunteer study will inform development of 4334 for treatment of hepatitis B virus SOUTH SAN FRANCISCO, Calif., Nov. 14,...